Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Page 1
Off-label Use of Balloon-Expandable Transcatheter Valves to Treat Pure Aortic Regurgitation.
Orzalkiewicz M, Foroni M, Chietera F, Bendandi F, Mazzapicchi A, Bruno AG, Ghetti G, Taglieri N, Marrozzini C, Galiè N, Palmerini T, Saia F. Orzalkiewicz M, et al. Among authors: galie n. Am J Cardiol. 2024 Apr 23:S0002-9149(24)00312-6. doi: 10.1016/j.amjcard.2024.04.030. Online ahead of print. Am J Cardiol. 2024. PMID: 38663573
In conclusion, TAVI in pure AR with oversized Sapien BEV showed good procedural and short-term outcomes when 20% oversizing was predictably achievable....
In conclusion, TAVI in pure AR with oversized Sapien BEV showed good procedural and short-term outcomes when 20% oversizing was predi …
Comparison of different treatment strategies in patients with chronic thromboembolic pulmonary hypertension: a single centre real-world experience.
Dardi F, Rotunno M, Guarino D, Suarez SM, Niro F, Loforte A, Taglieri N, Ballerini A, Magnani I, Bertozzi R, Donato F, Martini G, Manes A, Saia F, Pacini D, Galiè N, Palazzini M. Dardi F, et al. Among authors: galie n. Int J Cardiol. 2023 Nov 15;391:131333. doi: 10.1016/j.ijcard.2023.131333. Epub 2023 Sep 4. Int J Cardiol. 2023. PMID: 37673403
METHODS: All patients with CTEPH referred to our centre were included. We compare the short-term clinical, functional, exercise and haemodynamic effect of medical therapy (irrespective of subsequent treatment strategies), PEA and BPA (irrespective of previous/subsequent tr …
METHODS: All patients with CTEPH referred to our centre were included. We compare the short-term clinical, functional, exercise and h …
Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking.
Parisi V, Baldassarre R, Ferrara V, Ditaranto R, Barlocco F, Lillo R, Re F, Marchi G, Chiti C, Di Nicola F, Catalano C, Barile L, Schiavo MA, Ponziani A, Saturi G, Caponetti AG, Berardini A, Graziosi M, Pasquale F, Salamon I, Ferracin M, Nardi E, Capelli I, Girelli D, Gimeno Blanes JR, Biffi M, Galiè N, Olivotto I, Graziani F, Biagini E. Parisi V, et al. Among authors: galie n. Front Cardiovasc Med. 2023 Jun 21;10:1184361. doi: 10.3389/fcvm.2023.1184361. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37416917 Free PMC article.
CONCLUSIONS: ECG is a sensitive tool for early identification and long-term monitoring of cardiac involvement in patients with AFD, providing "instantaneous pictures" along the natural history of AFD. ...
CONCLUSIONS: ECG is a sensitive tool for early identification and long-term monitoring of cardiac involvement in patients with AFD, p …
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension.
Coghlan JG, Gaine S, Channick R, Chin KM, du Roure C, Gibbs JSR, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson VF, Galiè N. Coghlan JG, et al. Among authors: galie n. ERJ Open Res. 2023 Jan 16;9(1):00456-2022. doi: 10.1183/23120541.00456-2022. eCollection 2023 Jan. ERJ Open Res. 2023. PMID: 36687361 Free PMC article.
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes. Post hoc analyses of GRIPHON (NCT01106014) and exploratory analyses of TRITON (NCT02558231) suggested benefit of early selexipag initiat …
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcom …
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, Konstantinides SV; PEITHO-2 Investigators. Mavromanoli AC, et al. Among authors: galie n. Clin Res Cardiol. 2023 Oct;112(10):1372-1381. doi: 10.1007/s00392-022-02138-4. Epub 2022 Dec 21. Clin Res Cardiol. 2023. PMID: 36539534 Free PMC article. Clinical Trial.
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E. Paolisso P, et al. Among authors: galie n. Pharmacol Res. 2023 Jan;187:106597. doi: 10.1016/j.phrs.2022.106597. Epub 2022 Dec 5. Pharmacol Res. 2023. PMID: 36470546 Free PMC article.
AIMS: To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated with SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users). ...Secondary outcomes included i) in-hospital cardiovascular death, …
AIMS: To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated w …
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R, Delcroix M, Galié N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O, Torbicki A, Boyanova N, Chamitava L, Stein C, Channick RN. Souza R, et al. Among authors: galie n. Adv Ther. 2022 Sep;39(9):4374-4390. doi: 10.1007/s12325-022-02199-x. Epub 2022 Jul 12. Adv Ther. 2022. PMID: 35819570 Free PMC article. Clinical Trial.
Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in PAH patients. ...RESULTS: Of 742 patients randomised in SERAPHIN, 550 (74.1%) entered SERAPHIN OL (OL safety set); 242 patients were randomised to maciten …
Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in PAH patients. …
Ten-year follow-up of cardiac resynchronization therapy patients with non-ischemic dilated cardiomyopathy assessed by radionuclide angiography: a single-center cohort study.
Valzania C, Massaro G, Spadotto A, Muraglia L, Frisoni J, Martignani C, Ziacchi M, Diemberger I, Fanti S, Boriani G, Biffi M, Galié N. Valzania C, et al. Among authors: galie n. J Interv Card Electrophysiol. 2022 Sep;64(3):723-731. doi: 10.1007/s10840-022-01117-z. Epub 2022 Feb 17. J Interv Card Electrophysiol. 2022. PMID: 35175490
PURPOSE: Relatively few data are available on long-term survival and incidence of ventricular arrhythmias in cardiac resynchronization therapy (CRT) patients. ...Long-term risk for sustained ventricular arrhythmia was similar between CRT responders and non-responder …
PURPOSE: Relatively few data are available on long-term survival and incidence of ventricular arrhythmias in cardiac resynchronizatio …
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Galiè N, et al. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. Adv Ther. 2022. PMID: 34727317 Free PMC article. Clinical Trial.
The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH patients treated with selexipag. ...A large proportion of the population was receiving background therapy at selexipag initiation, providing fur …
The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH pati …
Response to Comment on Paolisso et al. Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care 2021;44:2158-2161.
Paolisso P, Bergamaschi L, Rambaldi P, Gatta G, Foà A, Angeli F, Fabrizio M, Casella G, Barbieri M, Galiè N, Marfella R, Pizzi C, Sardu C. Paolisso P, et al. Among authors: galie n. Diabetes Care. 2021 Nov;44(11):e201-e202. doi: 10.2337/dci21-0042. Diabetes Care. 2021. PMID: 34670794 No abstract available.
86 results